SCHEMBL5779734

SCHEMBL5779734

N#CC(Br)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.43
IDO1 P14902 3/20 0.36
TDO2 P48775 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CES2 O00748 1/20 0.34
RPS6KA3 P51812 1/20 0.34
JAK3 P52333 1/20 0.34
GPBAR1 Q8TDU6 4/20 0.34
RAPGEF3 O95398 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
KIF11 P52732 1/20 0.31
ALDH1A1 P00352 1/20 0.31
PKM P14618 1/20 0.31
TACR1 P25103 2/20 0.31
GAA P10253 1/20 0.31
CTSS P25774 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10959497 0.81 TRPA1 (0.52) TRPA1IDO1TDO2CES2GAA
SCHEMBL11398665 0.79 IDO1 (0.36) IDO1TDO2CES2TACR1
SCHEMBL8073025 0.76 TRPA1 (0.41) TRPA1
SCHEMBL28061635 0.75 TACR1 (0.37) IDO1TDO2L3MBTL1CES2RPS6KA3
SCHEMBL28284728 0.75 TACR1 (0.37) IDO1TDO2L3MBTL1CES2RPS6KA3
SCHEMBL27268122 0.73 CES2 (0.38) IDO1TDO2L3MBTL1CES2RPS6KA3
SCHEMBL8700783 0.71 TACR1 (0.40) IDO1TDO2CES2RAPGEF4ALDH1A1
SCHEMBL264836 0.71 TACR1 (0.40) IDO1TDO2CES2RAPGEF4ALDH1A1
SCHEMBL1649435 0.71 TACR1 (0.40) IDO1TDO2CES2RAPGEF4ALDH1A1
SCHEMBL14321104 0.71 IDO1 (0.39) IDO1TDO2CES2ALDH1A1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1795177-A 1, 2, 4-substituted 1, 2, 3, 4-tetrahydro-and 1, 2 dihydro-quinolines and 1, 2, 3, 4-tetrahydro-quinoxaline derivatives as CETP inhibitors for the treatment of atherosclerosis and obesity PFIZER PROD INC (US) 2006-06-28 CN disclosed
US-20060122224-A1 Quinoline and quinoxaline compounds BECHLE BRUCE M 2006-06-08 US disclosed
EP-1622872-A1 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY Pfizer Products Inc. (US) 2006-02-08 EP disclosed
WO-2006009819-A1 INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTIEN ARRAY BIOPHARMA INC. (US) 2006-01-26 WO disclosed
US-20050282812-A1 Inhibitors of cholesteryl ester transfer protein ARRAY BIOPHARMA INC. 2005-12-22 US disclosed
US-20040204450-A1 Quinoline and quinoxaline compounds PFIZER INC 2004-10-14 US disclosed
WO-2004085401-A1 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY PFIZER PRODUCTS INC. (US) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122224-A1 Quinoline and quinoxaline compounds LDLR, APOB, PON1 TRPA1 4260/4885IDO1 1293/4885TDO2 788/4885
US-20040204450-A1 Quinoline and quinoxaline compounds LDLR, APOB, PON1 TRPA1 4260/4885IDO1 1293/4885TDO2 788/4885
US-20050282812-A1 Inhibitors of cholesteryl ester transfer protein CETP, LCAT, MTTP TRPA1 4720/4885IDO1 4622/4885TDO2 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.